June 28, 2022
Bulletin from the Annual General Meeting in Oncopeptides AB (publ)
Media
June 23, 2022
CHMP issues a positive opinion recommending full approval of Oncopeptides Pepaxti in EU for patients with triple class refractory multiple myeloma
June 23, 2022
Fusion Pharmaceuticals Announces FDA Clearance Of IND For FPI-2059, An Investigational Small Molecule-Based Radiopharmaceutical Targeting Solid Tumors Expressing NTSR1
June 23, 2022
Targovax announces that the FDA has granted authorization to initiate clinical trials with the enhanced TG01 RAS vaccine in the USA
June 21, 2022
Nordic Nanovector to Seek Regulatory Feedback Following its Preliminary Review and Independent Data Evaluation of PARADIGME, its Phase 2b Trial with Betalutin® in R/R Follicular Lymphoma
June 20, 2022
Börje Haraldsson appointed CEO of Oncorena AB
June 17, 2022
Carisma Therapeutics to Host Webcast on Phase 1 Clinical Trial of Engineered Macrophage Therapy
June 16, 2022
BONESUPPORT achieves private coverage in South Africa
June 16, 2022
Vicore announces first human dosed with novel ATRAG, C106
June 14, 2022
Fusion Pharmaceuticals Presents Imaging Data From Cold Antibody Sub-Study In The Phase 1 Study Of FPI-1434
